Evolution of pathogens during vaccination programs

A recent publication in PLOS Biology summarized the current understanding of pathogen evolution.

Study: Pathogen evolution during vaccination campaigns. Image Credit: nobeastsofierce/Shutterstock
Study: Pathogen evolution during vaccination campaigns. Image Credit: nobeastsofierce/Shutterstock

Pathogen adaptation occurs when novel variants gain greater fitness in the current environment than their predecessors. Host immunity, whether vaccination- or infection-induced, could shape the existing habitat for pathogens. The speed at which new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged and the scale of the global SARS-CoV-2 vaccination efforts have raised questions about the impact of vaccination on viral evolution.

The temporal evolutionary dynamics for novel pathogens may involve two phases. During the first phase, hosts are immune-naïve, and selection favors adaptation to these hosts. In the second phase, the host population gradually acquires immunologic memory from infection or vaccination, and selection shifts favoring adaptation to these immunologically primed hosts. In the present study, researchers explored how pathogens in novel hosts evolve when hosts become immunologically primed.

Adaptation of pathogens and mechanisms

Adaptation of pathogens to immune-naïve and -primed hosts relies on the emergence of new variants and their fitness in different hosts. Fitness could be computed using absolute and relative growth rates. The absolute growth rate of infections helps determine if a variant could spread in the population. In contrast, the relative growth rate indicates whether the variant could increase in frequency, and displace the currently-dominant variant, viz., the wild-type.

The absolute growth rate must be positive for a variant to spread in the population. The selection coefficient (difference between growth rates of variant and wild-type) must be positive for a variant to increase its relative frequency. Variants could spread between hosts through immune evasion, suppression, exploitation, and life history adaptations, among others.

Traits such as enhanced affinity for host receptors, altered latency, large burst sizes, and tissue tropism changes underpin these mechanisms. In instances where host death or hospitalization limits transmission of the pathogen, infection- or vaccine-induced immunity could enhance transmission by decreasing disease severity. These ideas lead to classifying immunity-adapted variants in two ways.

First, an immunity-adapted variant is a generalist if adapted to naïve host populations. In contrast, an immunity-adapted variant is a specialist if it is maladapted to naïve hosts. Another way of categorization is to assess if the absolute growth rate is facilitated or inhibited by immunologic priming. The absolute growth rate of an immunity-facilitated variant increases with the increase in the proportion of primed hosts, whereas it decreases for immunity-inhibited variants.

Immunity decreases the magnitude of pathogen replication in two ways. The immune response minimizes pathogen load and rapidly clears the infection in primed hosts, and the high proportion of primed hosts in a population reduces the frequency of infected hosts. Effective vaccines and their rapid rollout restrict the emergence of new variants; however, pathogen adaptation could increase by leaky vaccines, which do not entirely prevent infection, and due to chronic infections in immunocompromised hosts.

Notably, many vaccines have not been undermined by the adaptation of pathogens. The lack of adaptation has been speculated to stem from two features associated with vaccination. First, because vaccination is prophylactic, it can limit the number of pathogens in vaccinated hosts and restrict the emergence/ transmission of novel variants. Second, vaccines generally elicit immune responses against multiple targets on the pathogen, making it difficult for the pathogen to circumvent the immune responses.  

Implications for SARS-CoV-2

Experimental evolution is the direct way of exploring how vaccines impact pathogen adaptation. Only one study has applied this approach, whereas most others are observational, focusing on pathogens with a long-term association with hosts. Mounting evidence suggests rapid adaptive evolution for SARS-CoV-2. Epidemiologic data indicate that most immunity-adapted SARS-CoV-2 variants are immunity-inhibited generalists.

The frequency of the Delta variant increased in countries with high and low vaccination coverage, suggesting it is a generalist variant. The more recent Omicron variant also appears to be immunity-inhibited, although it remains to be ascertained if the Omicron (sub)variants are specialists or generalists. So far, immunity-facilitated SARS-CoV-2 variants have not appeared, and it is possible that such variants would never emerge depending upon the available genetic variation.

Nevertheless, specialist variants are likely if SARS-CoV-2 undergoes further adaptation in response to immunologic priming. Moreover, next-generation vaccines or modified vaccination schedules may be required in the future to tackle SARS-CoV-2 evolution. Multiple SARS-CoV-2 vaccines have been deployed, and vaccination schedules are continually adjusted.

If this diversity leads to immunologic heterogeneity in the population, then natural selection would favor distinct variants at different times/locations or permit the co-existence of several variants. As such, it is critical to tweak vaccination programs to contain infections continually. The more a vaccine can suppress transmission, target different epitopes, and effectively inhibit infection and replication within hosts, the better it would be to curtail the adaptation rate of the pathogen.

Concluding remarks

In the early stages of pandemics, generalist variants are expected to increase in frequency. Later on, the evolution of pathogens involves adaptations to immune-primed hosts and a decrease in adaptation to naïve hosts. Immunity could inhibit both generalists and specialists, wherein the growth rate decreases with the increase in the proportion of primed hosts.

The SARS-CoV-2 variants have been immunity inhibited so far, and many are generalists, which would have increased in frequency regardless of the vaccination efforts. At some point, further adaptation could occur from the spread of specialists, although whether they will be immunity-inhibited or -facilitated would depend on viral mutations.

Journal reference:
Tarun Sai Lomte

Written by

Tarun Sai Lomte

Tarun is a writer based in Hyderabad, India. He has a Master’s degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. He enjoys reading research papers and literature reviews and is passionate about writing.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sai Lomte, Tarun. (2022, September 27). Evolution of pathogens during vaccination programs. News-Medical. Retrieved on December 08, 2022 from https://www.news-medical.net/news/20220927/Evolution-of-pathogens-during-vaccination-programs.aspx.

  • MLA

    Sai Lomte, Tarun. "Evolution of pathogens during vaccination programs". News-Medical. 08 December 2022. <https://www.news-medical.net/news/20220927/Evolution-of-pathogens-during-vaccination-programs.aspx>.

  • Chicago

    Sai Lomte, Tarun. "Evolution of pathogens during vaccination programs". News-Medical. https://www.news-medical.net/news/20220927/Evolution-of-pathogens-during-vaccination-programs.aspx. (accessed December 08, 2022).

  • Harvard

    Sai Lomte, Tarun. 2022. Evolution of pathogens during vaccination programs. News-Medical, viewed 08 December 2022, https://www.news-medical.net/news/20220927/Evolution-of-pathogens-during-vaccination-programs.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
How does imprinted SARS-CoV-2 humoral immunity drive convergent Omicron evolution?